Fusion molecules and treatment of IgE-mediated allergic diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 4, 2007
Grant Date -
May 1, 2003
app pub date -
May 1, 2001
filing date -
May 1, 2001
priority date (Note) -
In Force
status (Latency Note)
Importance
|
US Family Size
|
Non-US Coverage
|
|
Patent Longevity
|
Forward Citations
|
Abstract
The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and Fc.epsilon.RI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.
First Claim
Other Claims data not available
